D'Amato Smeralda, Squeri Raffaele, La Fauci Vincenza, Pantò Giuseppe, Esposito Ennrica Maria, Denaro Federica, Visalli Giovanna, Giunta Ioselita, Venuto Roberto, Privitera Antonino, D'Urso Lorenzo, Cortese Rosaria, Mazzitelli Francesco, Ceccio Concetta, Fedele Franco, Maisano Daniele, Trimarchi Giuseppe, Genovese Cristina
.
a:1:{s:5:"en_US";s:18:"IGIENE OSPEDALIERA";}.
Acta Biomed. 2021 Oct 19;92(S6):e2021415. doi: 10.23750/abm.v92iS6.12261.
Severe Acquired Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) infection represents an unprecedented public health problem and, at present, vaccination is the only weapon available to combat the infection. The simplest and most immediate method to quantify the response of the subject's immune system to vaccination and / or infection is the serological assessment of the antibody titer. The objective of our study was 1) to evaluate the presence of antibody responses in a sample of healthcare workers subjected to a complete vaccination course as per ministerial provisions (double dose for negatives and single dose for ex-SARS-CoV subjects -2 positive) with Comirnaty vaccine (Pfizer / BioNTech) 2) evaluate the presence of statistically significant associations for sex, age and previous positive swab.
the antibody levels of both nucleocapsid antibodies and anti-Sars-CoV2 Spike antibodies of the study subjects were examined with the electrochemiluminescent immunoassay (ECLIA) method developed by Roche®. The cut-off value, as suggested by the manufacturer, for anti-nucleocapsid antibodies was 1 COI, while the Ig Spike value was 0.8 I / mL. The study sample was stratified by age (≤45 years, 46-55, ≥56 years old), previous positive molecular swab, gender and IgG S1 / S2 values at the completed vaccination course (≤200, ≥200 AU / mL ). Statistical analyzes were carried out with the R software.
almost all of the sample (89.45%) showed IgG Spike values> 200 AU / mL with statistically significant associations in relation to sex (greater in females, p≤0.05), to previous swab positivity in the presence of a vaccine dose (n = 44; p <0.001) and at age (with greater antibody response in subjects under 45; p <0.001).
The current study confirms what is reported in the literature. In the light of the results obtained, it could be interesting to promote studies that evaluate the antibody titers trend over time a) in women of childbearing age and postmenopausal age b) in particular categories of subjects with chronic degenerative diseases to assess the actual need for doses booster, it being understood that the immune system response is guaranteed by both cellular and humoral immunity and that the antibody titer does not faithfully reflect the protection obtained.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染是一个前所未有的公共卫生问题，目前，疫苗接种是对抗该感染的唯一可用武器。量化受试者免疫系统对疫苗接种和/或感染反应的最简单、最直接的方法是血清学评估抗体滴度。我们研究的目的是：1）评估一组医护人员样本中抗体反应的存在情况，这些医护人员按照部长级规定完成了完整的疫苗接种疗程（阴性者接种两剂，曾感染过SARS-CoV-2呈阳性者接种一剂），使用的是Comirnaty疫苗（辉瑞/生物科技公司）；2）评估性别、年龄和之前拭子检测呈阳性之间是否存在统计学上的显著关联。
采用罗氏公司开发的电化学发光免疫分析法（ECLIA）检测研究对象的核衣壳抗体和抗SARS-CoV-2刺突抗体的水平。制造商建议的抗核衣壳抗体的临界值为1 COI，而Ig刺突值为0.8 I/mL。研究样本按年龄（≤45岁、46 - 55岁、≥56岁）、之前分子拭子检测呈阳性情况、性别以及完成疫苗接种疗程时的IgG S1/S2值（≤200、≥200 AU/mL）进行分层。使用R软件进行统计分析。
几乎所有样本（89.45%）的IgG刺突值>200 AU/mL，在性别（女性更高，p≤0.05）、接种一剂疫苗时之前拭子检测呈阳性情况（n = 44；p <0.001）和年龄方面（45岁以下受试者抗体反应更强；p <0.001）存在统计学上的显著关联。
本研究证实了文献中的报道。鉴于所获得的结果，开展以下研究可能会很有意思：a）评估育龄期和绝经后女性随着时间推移抗体滴度的变化趋势；b）评估患有慢性退行性疾病的特定类别受试者的抗体滴度变化趋势，以评估实际的加强剂量需求，需要明白的是，免疫系统的反应由细胞免疫和体液免疫共同保证，且抗体滴度并不能如实反映所获得的保护。
